Latest Insider Transactions at Onconova Therapeutics, Inc. (ONTX)
This section provides a real-time view of insider transactions for Onconova Therapeutics, Inc. (ONTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Onconova Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Onconova Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 18
2024
|
Mark Patrick Guerin CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,221
-5.35%
|
$0
$0.47 P/Share
|
|
Jun 10
2024
|
Mark Patrick Guerin CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,500
+11.71%
|
-
|
|
Apr 01
2024
|
Robert Redfield Acting Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
97,500
+50.0%
|
-
|
|
Apr 01
2024
|
Iain D. Dukes Executive Chairman |
BUY
Grant, award, or other acquisition
|
Indirect |
1,645,100
+50.0%
|
-
|
|
Apr 01
2024
|
Iain D. Dukes Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
134,237
+41.74%
|
-
|
|
Apr 01
2024
|
Nikolay Savchuk Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
2,530,632
+50.0%
|
-
|
|
Apr 01
2024
|
Nikolay Savchuk Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
134,237
+41.74%
|
-
|
|
Apr 01
2024
|
Werner Cautreels Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+50.0%
|
-
|
|
Apr 01
2024
|
Charles David Pauza Chief Science Officer Virology |
BUY
Grant, award, or other acquisition
|
Direct |
97,500
+50.0%
|
-
|
|
Mar 14
2024
|
Steven M Fruchtman PRESIDENT, CHIEF EXECUTIVE OFF |
SELL
Payment of exercise price or tax liability
|
Direct |
8,727
-10.45%
|
$0
$0.9 P/Share
|
|
Mar 14
2024
|
Mark Patrick Guerin CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,591
-6.72%
|
$0
$0.9 P/Share
|
|
Mar 13
2024
|
Steven M Fruchtman PRESIDENT, CHIEF EXECUTIVE OFF |
BUY
Exercise of conversion of derivative security
|
Direct |
23,111
+21.67%
|
-
|
|
Mar 13
2024
|
Mark Patrick Guerin CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
8,666
+18.35%
|
-
|
|
Feb 07
2024
|
Steven M Fruchtman PRESIDENT, CHIEF EXECUTIVE OFF |
SELL
Payment of exercise price or tax liability
|
Direct |
9,212
-13.23%
|
$0
$0.67 P/Share
|
|
Feb 07
2024
|
Steven M Fruchtman PRESIDENT, CHIEF EXECUTIVE OFF |
BUY
Exercise of conversion of derivative security
|
Direct |
21,320
+23.44%
|
-
|
|
Feb 07
2024
|
Mark Patrick Guerin CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,443
-7.55%
|
$0
$0.67 P/Share
|
|
Feb 07
2024
|
Mark Patrick Guerin CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,900
+17.58%
|
-
|
|
Aug 03
2023
|
Mark Patrick Guerin CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,422
-5.29%
|
$1,422
$1.02 P/Share
|
|
Aug 03
2023
|
Steven M Fruchtman PRESIDENT, CHIEF EXECUTIVE OFF |
SELL
Payment of exercise price or tax liability
|
Direct |
4,744
-8.94%
|
$4,744
$1.01 P/Share
|
|
Aug 02
2023
|
Mark Patrick Guerin CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,750
+15.02%
|
-
|
|
Aug 02
2023
|
Steven M Fruchtman PRESIDENT, CHIEF EXECUTIVE OFF |
BUY
Exercise of conversion of derivative security
|
Direct |
12,567
+19.15%
|
-
|
|
Jun 12
2023
|
Mark Patrick Guerin CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,575
-6.65%
|
$1,575
$1.14 P/Share
|
|
Jun 12
2023
|
Mark Patrick Guerin CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,500
+18.84%
|
-
|
|
Feb 07
2023
|
Steven M Fruchtman PRESIDENT, CHIEF EXECUTIVE OFF |
SELL
Payment of exercise price or tax liability
|
Direct |
6,977
-14.7%
|
$6,977
$1.36 P/Share
|
|
Feb 07
2023
|
Steven M Fruchtman PRESIDENT, CHIEF EXECUTIVE OFF |
BUY
Exercise of conversion of derivative security
|
Direct |
21,320
+31.0%
|
-
|
|
Feb 07
2023
|
Mark Patrick Guerin CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,785
-8.94%
|
$1,785
$1.36 P/Share
|
|
Feb 07
2023
|
Mark Patrick Guerin CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,900
+25.67%
|
-
|
|
Feb 07
2023
|
Mark S. Md Gelder CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,242
-10.59%
|
$1,242
$1.36 P/Share
|
|
Feb 07
2023
|
Mark S. Md Gelder CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,833
+33.21%
|
-
|
|
Aug 03
2022
|
Mark Patrick Guerin CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,355
-9.39%
|
$1,355
$1.32 P/Share
|
|
Aug 03
2022
|
Mark S. Md Gelder CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,135
-16.14%
|
$1,135
$1.32 P/Share
|
|
Aug 03
2022
|
Steven M Fruchtman PRESIDENT, CHIEF EXECUTIVE OFF |
SELL
Payment of exercise price or tax liability
|
Direct |
4,562
-14.86%
|
$4,562
$1.32 P/Share
|
|
Aug 02
2022
|
Mark Patrick Guerin CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,750
+24.76%
|
-
|
|
Aug 02
2022
|
Mark S. Md Gelder CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,650
+39.81%
|
-
|
|
Aug 02
2022
|
Steven M Fruchtman PRESIDENT, CHIEF EXECUTIVE OFF |
BUY
Exercise of conversion of derivative security
|
Direct |
12,566
+29.05%
|
-
|
|
Jan 28
2022
|
Abraham N. Oler SVP Corp Dev & Gen Counsel |
BUY
Open market or private purchase
|
Direct |
1,500
+5.77%
|
$1,500
$1.67 P/Share
|
|
Jan 21
2022
|
Abraham N. Oler SVP Corp Dev & Gen Counsel |
BUY
Open market or private purchase
|
Direct |
1,500
+6.12%
|
$3,000
$2.02 P/Share
|
|
Jan 14
2022
|
Abraham N. Oler SVP Corp Dev & Gen Counsel |
BUY
Open market or private purchase
|
Direct |
1,500
+6.52%
|
$3,000
$2.2 P/Share
|
|
Jan 07
2022
|
Abraham N. Oler SVP Corp Dev & Gen Counsel |
BUY
Open market or private purchase
|
Direct |
1,500
+6.97%
|
$3,000
$2.39 P/Share
|
|
Nov 19
2021
|
Abraham N. Oler SVP Corp Dev & Gen Counsel |
BUY
Open market or private purchase
|
Direct |
1,000
+5.12%
|
$3,000
$3.16 P/Share
|
|
Nov 18
2021
|
Abraham N. Oler SVP Corp Dev & Gen Counsel |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
5,000
+22.21%
|
$15,000
$3.0 P/Share
|
|
Sep 28
2021
|
Mark S. Md Gelder CHIEF MEDICAL OFFICER |
BUY
Open market or private purchase
|
Direct |
2,381
+50.0%
|
$9,524
$4.2 P/Share
|
|
Sep 28
2021
|
Abraham N. Oler SVP Corp Dev & Gen Counsel |
BUY
Open market or private purchase
|
Direct |
2,381
+15.98%
|
$9,524
$4.2 P/Share
|
|
Sep 28
2021
|
James J Marino |
BUY
Open market or private purchase
|
Direct |
5,952
+21.81%
|
$23,808
$4.2 P/Share
|
|
Sep 28
2021
|
Steven M Fruchtman PRESIDENT, CHIEF EXECUTIVE OFF |
BUY
Open market or private purchase
|
Direct |
2,381
+11.61%
|
$9,524
$4.2 P/Share
|
|
Feb 16
2021
|
Mary Teresa Shoemaker |
BUY
Open market or private purchase
|
Direct |
13,000
+20.4%
|
$13,000
$1.0 P/Share
|
|
Feb 16
2021
|
James J Marino |
BUY
Open market or private purchase
|
Direct |
25,000
+9.78%
|
$25,000
$1.0 P/Share
|
|
Feb 16
2021
|
Steven M Fruchtman PRESIDENT, CHIEF EXECUTIVE OFF |
BUY
Open market or private purchase
|
Direct |
20,000
+7.81%
|
$20,000
$1.0 P/Share
|
|
Feb 16
2021
|
Mark Patrick Guerin CFO |
BUY
Open market or private purchase
|
Direct |
15,000
+9.36%
|
$15,000
$1.0 P/Share
|
|
Feb 16
2021
|
Abraham N. Oler SVP Corp Dev & Gen Counsel |
BUY
Open market or private purchase
|
Direct |
12,000
+7.32%
|
$12,000
$1.0 P/Share
|